leave the primary site and metastasize to other locations ( Fig. 1 ).
Cell-Cell Interactions
Angiogenesis not only depends on growth factors but is also influenced by specific cell-cell and cell-ECM contacts. For example, antibodies to E-selectin, a transmembrane cell-adhesion glycoprotein, or sialyl-Lewis X or A, a cell-surface sialylated glycan, interfere with lumen formation in in vitro assays of blood vessel tube formation (8) . Although E-selectin induces endothelial cell migration and angiogenesis in the rat cornea, E-selectin is neither a mitogen, nor does it influence endothelial cell mitogen production (9) . In addition, a combined knockout of p-and E-selectin in mice does not result in blood vesscd deformations (10) .
Expression levels of immunoglobulin-like molecules, such as intercellular adhesion molecule 1 and vascular adhesion molecule 1 (VCAM-l), are induced in endothelial cells after stimulation with inflammatory cytokines [interferon ' Y (IFN-'Y), interleukin 1 (IL-l), tumor necrosis factor a (TNF-a), or lipopolysaccharides]. VCAM-l induces angiogenesis in vivo and integrin a4131-dependent migration of endothelial cells in vitro. VCAM-l may act as an angiogenic stimulator through its interaction with a4{31, however, VCAM-l does not affect endothelial cell proliferation. Another cell adhesion molecule, 11, an inducer of neurite outgrowth, has been shown to interact with the integrins av{33, aIIb{33, av{31, or a5131, present on platelets or endothelial cells via an RGD motif in the 11 molecule (11). Tumor-induced angiogenesis. Angiogenesis, the formation of new blood vessels from preexisting blood vessels during tumor-induced angiogenesis, can be divided into three phases. Angiogenic growth factors such as basic fibroblast growth factor (bFGF) or vascular endothelial growth factor (VEGF) are secreted from tumor cells. Tumor-secreted growth factors induce cell proliferation, cell invasion, expression of integrin av{33 on vascular cells, and matrix degradation of surrounding extracellular matrix. The proteolytic degradation of the surrounding matrix microenvironment is a crucial step leading to new blood vessel growth and the maturation of the newly sprouted blood vessels.
Cell-Matrix Interactions
Cell adhesion to the extracellular matrix is mediated by integrins, which are heterodimeric transmembrane proteins that mediate cell-ECM interactions, and comprise a diverse family of over 15 a and 8 f3 subunits. Integrin subunits can heterodimerize in at least 20 different combinations. Different integrin combinations may recognize a single extracellular matrix (ECM) ligand, and other integrins may bind several different ECM proteins. Integrins are known to mediate not only the specificity of cell adhesion to a variety of matrix proteins but also the regulation of the cell cycle (12-14) and cell migration (15,16). Integrin ligation is known to induce a wide range of intracellular Signalling events, including tyrosine phosphorylation of focal adhesion kinase and other focal contact-associated proteins (17), elevated intracellular pH and Ca2+ levels, inositol lipid synthesis, cyclin synthesis, and the expression of immediate early genes (12,13,18-22). Prevention of integrin interactions suppresses cellular growth or induces apoptotic cell death (2, (23) (24) (25) . Multiple integrins are expressed on endothelial cells, mediating adhesion to a wide variety of ECM proteins including fibronectin, vitronectin, laminin, collagen types I and IV, von Wille brand factor, fibrinogen, and denatured collagen (26).
Cell-Extracellular Matrix Interactions during Angiogenesis
Angiogenesis involves multiple interactions between the ECM and vascular cells. Dynamic remodeling of the extracellular matrix surrounding blood vessels facilitates several steps during angiogenesis, including matrix degradation and deposition of new ECM components. Laminin, a major component of basement membranes, is important during capillary tube formation (6, 27) . Various forms of collagen (types I, III, IV, and V) are also deposited during endothelial tube formation in vitro (28, 29) . The proteolysis of collagen can also influence endothelial tube formation since inhibition of matrix metalloproteinases (MMPs) block this process (30) (31) (32) .
In vivo, ECM proteins are deposited during vasculogenesis and angiogenesis. For example, fibronectin is deposited followed by laminin during wound healing in the skin and in retinal and intraembryonal vasculogenesis (33) (34) (35) . The role of collagens has been strongly implicated in angiogenesis through studies by Ingber and Folkman, who demonstrated that inhibition of collagen deposition and triple-helix formation, as well as inhibition of collagen cross-linking, prevented angiogenesis (36) . Furthermore, function-blocking anti-alf31 and a2f31 antibodies blocked VEGF-induced angiogenesis (37) . De novo synthesis of collagen has also been shown to be important during angiogenesis (38, 39) . Genetic evidence for the role of collagen during angiogenesis is provided by a targeted gene knockout of collagen type I a I-chain, which resulted in the rupture of blood vessels, indicating defects in early blood vessel development (40) .
In addition to collagen deposition, collagen degradation by MMPs has been implicated as an important step during the invasive stage of an-giogenesis. For example, angiogenic inducers, such as bFGF, phorbal-12-myristate-13-acetate (PMA), and TNF-a, stimulate the expression of MMPs in endothelial cells (41, 42) . Tissue inhibitors of metalloproteinases (TIMPs), which regulate MMP activity on the cell surface, have been shown to inhibit angiogenesis in the chick embryo yolk-sac, chick chorioallantoic membrane (CAM), and rat cornea (42) (43) (44) . The temporal and spatial coordination of collagen synthesis and collagen proteolysis in the ECM surrounding vascular cells is essential during angiogenesis. During the early phase of angiogenesis, local matrix degradation by MMPs may be required for invasion of pre-existing vascular cells through the basement membrane and surrounding stroma; this is followed by vascular cell migration and proliferation, which may depend on nascent expression and deposition of collagen. The proteolytic degradation of collagen may expose cryptic adhesive sites that are crucial for the invasive and, perhaps later, the migration phases of angiogenesis. For example, proteolysis of the intact collagen triple helix (types I and VI) can expose cryptic RGD-binding sites that are recognized by the integrin avf33 (24, 45, 46) . Integrin aVf33 is expressed preferentially on the surface of vascular cells undergoing angiogenesis in the chick CAM (25,47). Endothelial cells may use the cryptic RGD sites as a provisional matrix during the invasive and proliferative phases, providing a possible mechanism for coordinating adhesive and proteolytic activities during angiogenesis. Expression of collagen type IV and laminin during the deposition of new basement membrane may then facilitate differentiation and lumen formation during the later stages of angiogenesis (36) .
av Integrins and Angiogenesis
Of the wide spectrum of integrin subunit combinations that are expressed on the surface of cells, the aVf33 integrin has been identified as having an especially interesting expression pattern and distinct functional properties in vascular cells during angiogenesis. Integrin aVf33 is a receptor for a variety of ECM ligands with an exposed RGD moiety, including vitronectin, fibronectin, fibrinogen, laminin, collagen, von Willebrand factor, osteopontin, and adenovirus penton base (16, 48, 49) .
Integrin aVf33 has a very limited tissue distribution as it is not typically expressed on epithelial cells and only at low levels on intestinal, vascular, and uterine smooth-muscle cells (50) . This receptor is also expressed on some activated leukocytes, macrophages, and osteoclasts, where it may function during bone resorption (51) (52) (53) . Some invasive tumors such as metastatic melanoma (54) and late-stage glioblastoma (55) also express avf33. Among the most prominent aVf33 expression levels have been identified in cytokine-activated endothelial or smooth muscle cells, especially on blood vessels in granulation tissue and tumors (25, 47, 56, 57) . The expression of aVf33 on blood vessels suggests that it may be important for vascular cell proliferation and for migration events associated with restenosis and angioplasty. The vascular smooth-muscle cell migration that occurs during restenosis is dependent on aVf33 ligation and is accompanied by increased expression levels of osteopontin, an aVf33 ligand (58) . A function-blocking anti-f33-antibody has been shown to be beneficial in high-risk angioplasty patients (59) . In addition to the possible role of aVf33 during restenosis, there has been a significant advance in the understanding of the possible role of integrin aVf33 during angiogenesis and vascular remodeling in recent years.
Integrin aVf33 is expressed at low level in quiescent or normal blood vessels, but it is induced following exposure to cytokines, growth factors, or tumors (47) . bFGF induces f33 mRNA and surface expression on cultured human dermal microvascular endothelial cells (57, 60) . The bFGF-induced increase in aVf33 mRNA has been shown to be dependent on the nascent expression of the Hox D 3 homeobox gene followed by aVf33 expression (61) . Furthermore, aVf33 protein expression is induced by bFGF on blood vessels in the chick CAM (47) and on the rabbit cornea (62) . aVf33 expression in vascular cells is also induced by human tumor cells cultured on the CAM (25,47) and during wound healing (47), macular degeneration, diabetic retinopathy, and other neovascular diseases of the eye (63) .
The up-regulation of aVf33 during angiogenesis suggests that integrins may have an important function during angiogenesis. In fact, disruption of integrin aVf33 ligation with antibody (LM609) or cyclic peptide antagonists of aVf33 prevent blood vessel formation in the chick CAM, quail embryo, rabbit cornea, mouse retina, and in human skin transplanted onto severe combined immunodeficiency disease (SCID) mice (47, 62, (64) (65) (66) blocked tumor growth but induced tumor regression (25). Histological examination of tumors treated with the aVf33 antagonists revealed few if any viable tumor cells or detectable blood vessels (25). Cytokine or tumor cell-stimulated blood vessels treated with the aVf33 antagonists have been shown to undergo programmed cell death (apoptosis) in response to administration of the antagonists (47) . These findings suggest that integrin aVf33 can provide specific cell survival signals that facilitate vascular cell proliferation during angiogenesis (Fig. 3) .
A genetic approach to examining the role of the aV and the 133 integrin subunits has provided some insight into the role of these molecules during vasculogenesis and angiogenesis. In Glanzmann thrombobastemia patients, who lack functional 133 integrin protein (68, 69) , there appears to be normal development of blood vessels, although the woundhealing response is associated with extensive bleeding. This suggests that although functional 133 levels are diminished, perhaps the expression of integrin avf35, another RGD-specific integrin, may compensate for the absence of functional avf33. In fact, integrin aVf35 can potentiate a distinct pathway of VEGF-induced angiogenesis (62) .
Genetic knockout experiments of the aV gene in mice have shown that some mice survive to term, but die shortly after birth (70) . These av-null mice have extensive brain and intestinal hemorrhaging, which indicates a defect in blood vessel integrity demonstrating the requirement for the expression of aV integrin in blood vessel formation and/or maturation. Other organs have apparently normal vascularization (70) , suggesting that animals lacking aV integrins can compensate to some degree by perhaps utilizing other integrin-dependent adhesion pathways. Interestingly, mice lacking the 133 subunit while having a bleeding disorder contain normal brain and intestinal blood vessels (71) . Therefore, if one considers that brain and intestinal blood vessel development is disrupted by an aV knockout. an integrin other than aVf33 must be required for blood vessels in these organs (Table 1) .
Integrin avfJ3 and Vascular Cell Survival
Systemic administration of aVf33 antagonists has been shown to induce apoptosis in cytokine or tumor cell-activated blood vessels (25). In fact, primary endothelial cells are known to be anchorage-dependent for growth and can undergo apoptosis when treated with anti-integrin function-blocking antibodies (23,75). These results suggest that ligation of aVf33 on vascular cells may mediate a signaling event that is essential for the survival and differentiation of vascular cells undergoing angiogenesis in vivo. Using DNA laddering and measurements of free 3'OH groups from fragmented DNA as markers of apoptosis in endothelial cells, aVf33 antagonists induced apoptosis after 48 hr of treatment (25). The aVf33 antagonists (71) administered during angiogenesis in the chick CAM also induced endothelial cell, p53-dependent DNA-binding activity, which regulates the cell-cycle inhibitor p21 WAFIICIPI (76) . In cultured endothelial cells, ligation of av(33 with immobilized antibody reduced the p53 activity and subsequent p21 WAFIICIPI protein levels. Ligation of av(33 was also shown to increase the expression of Bcl-2 and decrease Bax levels in primary endothelial cells, resulting in an increase in the Bcl-2:Bax ratio (75), a signal known to promote cell survival (77) . Therefore, ligand binding by endothelial cell av(33 may suppress apoptosis and conflicting growth-arrest signals, facilitating the proliferation and differentiation of new blood vessels (Fig. 3) . It is important to point out that mice clearly survive without p53, indicating that alternative or compensatory apoptotic mechanisms can allow normal development. The fact that aV integrin antagonists activate a p53-dependent cell death pathway suggests that mice lacking p53 may also not depend on aV integrins for vascular development. This in turn may account for the presence of blood vessels in mice lacking aV integrins.
Regulation of MAP Kinase Activity in Angiogenesis
Angiogenesis is initiated by growth factors and depends on cell adhesion events to mediate the signaling events that lead to vascular cell proliferation, migration, and differentiation. Integrins and growth factor receptors have been co-localized on the cell surface and appear to cooperate in their capacity to activate the rasl mitogen-activated protein (MAP) kinase pathway (78, 79) . Although growth factors can initiate MAP kinase activity and vascular cell proliferation, it is not clear how these signals ultimately lead to vascular remodeling events, which involve endothelial cell invasion and lumen formation of angiogenic sprouts in vivo.
We have recently identified two bFGF-induced ERK activation signals required for angiogenesis in vascular cells (67 For example, exposure of PC 12 cells to epidermal growth factor induces a rapid and transient MAP kinase activity leading to cell proliferation, while nerve growth factor induces cell differentiation due to a sustained MAP kinase activation (81) .
It is possible that during angiogenesis, ligation of aVf33 through appropriate matrix contacts provides the positional or molecular cues necessary for sustained ERK activity. This may allow prolonged cell survival and differentiation of only those cells that are in the appropriate matrix microenvironment. In fact, antagonists of aVf33 caused apoptosis of proliferating vascular cells undergoing angiogenesis in the chick CAM, and this was associated with increased endothelial cell p53 activity. Interestingly, MAP kinase activity can regulate both p53 activity (82) and cell survival (76) in vitro. These observations indicate that sustained activation of ERK by aVf33 ligation during angiogenesis may suppress p53 activity, thereby promoting vascular cell survival and the maturation of newly sprouting blood vessels (Fig. 3) .
Two pathways of angiogenesis have recently been identified, based on their dependence on the related but distinct integrins aVf33 and aVf35 (62) . In studies in both the rabbit corneal eye pocket and CAM angiogenesis assays, anti-avf33 monoclonal antibody antagonists blocked bFGFinduced angiogenesis, whereas anti-avf35 antagonists blocked VEGF-induced angiogenesis. Furthermore, inhibition of the PKC pathway blocked the VEGF-induced angiogenesis specifically but did not affect bFGF-induced angiogenesis. These distinctions between these individual pathways of angiogenesis suggest that further examination of the specific signaling requirements of specific growth factors during angiogenesis may lead to a better understanding of the growth factor requirements during tumor-induced angiogenesis.
Future Perspectives
The elucidation of the molecular basis of angiogenesis remains a challenge because of the complex ECM-vascular cell interactions that must be temporally and spatially coordinated. Further examination of the signaling events transduced by cell adhesion molecules to the smooth muscle and endothelial cells will probably reveal mechanisms by which cells process cytokine or growth factor stimuli to effect changes in intracellular phosphorylation cascades, gene expression levels, and ECM-associated enzymatic activities. The coordinated response to these inputs may direct the processes of vascular cell invasion, migration, proliferation, and differentiation during angiogenesis.
Clinical trials are now ongoing to examine the effects of a humanized form of the anti-avf33 antibody, LM609 (Vitaxin) ( Table 1 ). This antibody is being administered to late-stage cancer patients in a dose-escalation study. A second trial is now underway using a small cyclic peptide antagonist of both aVf33 and avf35. Initial clinical results show these antagonists are not only safe but may be providing clinical benefit in a number of patients.
altered hematopoiesis in mice deficient in both Pand E-selectins. 
